Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR2 | O43614 | 5/20 | 0.67 |
| ▸ | PDE5A | O76074 | 8/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | HTR2B | P41595 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | FAP | Q12884 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL667566 | 0.89 | HCRTR2 (0.69) | HCRTR2PDE5AHCRTR1HTR1AOPRM1 | |
| SCHEMBL666987 | 0.81 | HCRTR2 (0.76) | HCRTR2HCRTR1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL667875 | 0.80 | HCRTR2 (1.00) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL667759 | 0.77 | HCRTR2 (0.80) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL667564 | 0.75 | HCRTR2 (0.89) | HCRTR2HCRTR1LMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL666493 | 0.74 | HCRTR2 (0.71) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL7919613 | 0.74 | HCRTR2 (0.57) | HCRTR2HCRTR1HTR1AOPRM1DRD3 | |
| SCHEMBL2276551 | 0.73 | HCRTR2 (0.61) | HCRTR2PDE5AHCRTR1HTR1AOPRM1 | |
| SCHEMBL2277515 | 0.73 | HCRTR2 (0.61) | HCRTR2PDE5AHCRTR1HTR1AOPRM1 | |
| SCHEMBL2275632 | 0.72 | HCRTR2 (0.66) | HCRTR2HCRTR1HTR1AOPRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703770-B2 | Pyridazine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | claimed |
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-02-23 | — | — | US | claimed |
| EP-2349267-A1 | PYRIDAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2011-08-03 | — | — | EP | claimed |
| WO-2010051238-A1 | PYRIDAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | claimed |
| EP-2349267-B1 | PYRIDAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-06-25 | — | — | EP | disclosed |
| US-8703770-B2 | Pyridazine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703770-B2 | Pyridazine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| US-8703770-B2 | Pyridazine carboxamide orexin receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2014-04-22 | — | — | US | disclosed |
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-02-23 | — | — | US | disclosed |
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-02-23 | — | — | US | disclosed |
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-02-23 | — | — | US | disclosed |
| WO-2010051238-A1 | PYRIDAZINE CARBOXAMIDE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2010-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046289-A1 | Pyridazine Carboxamide Orexin Receptor Antagonists | HCRTR2, HCRTR1, NPY5R | HCRTR2 1/4885PDE5A 2079/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.